As part of Myeloma Patients Europe’s (MPE) ongoing work to ensure that the patient voice is fully represented and to strengthen organisations’ and individuals’ ability to advocate effectively, in 2017, MPE created the Advocate Development Programme (ADP). The ADP is a 12-month training programme designed to develop participants’ advocacy knowledge and skills to serve patients better locally, nationally and across Europe. Through the course, participants improve their understanding of clinical research and development, mechanisms of accessing diagnostics and drugs, interaction with stakeholders, including clinicians and industry, and the basics of evidence-based advocacy.
Katie Joyner, Co-Chief Executive Officer (CEO) at MPE, and two ADP participants, Fionnuala Duffy and Vicent Claus, explain in this video the main objectives and details of this programme: